[Skip to Content]
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

September 2019, Vol 5, No. 9, Pages 1247-1376

Original Investigation

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2019;5(9):1268-1275. doi:10.1001/jamaoncol.2019.1467

This open-label, phase 2 randomized clinical trial assesses whether maintenance therapy with single-agent panitumumab was noninferior to panitumumab plus combined fluorouracil and leucovorin calcium among patients with RAS wild-type metastatic colorectal cancer.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(9):1276-1282. doi:10.1001/jamaoncol.2019.1478

This phase 2 randomized clinical trial assesses whether pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone enhances tumor response in patients with metastatic non–small cell lung cancer.

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

Abstract Full Text
JAMA Oncol. 2019;5(9):1283-1290. doi:10.1001/jamaoncol.2019.1449

This phase 2 single-arm study evaluates outcomes following pembrolizumab treatment after locally ablative therapy in patients with oligometastatic non–small cell lung cancer.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Abstract Full Text
JAMA Oncol. 2019;5(9):1293-1301. doi:10.1001/jamaoncol.2019.1568

This cohort study investigates the association of prediagnostic serum immune markers with the subsequent diagnosis of stable monoclonal gammopathy of undetermined significance vs progression to multiple myeloma.

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1304-1309. doi:10.1001/jamaoncol.2019.1856

This secondary analysis of the Stockholm Tamoxifen (STO-3) clinical trial, which was conducted from 1976 to 1990, assessed the long-term survival associated with tamoxifen therapy in postmenopausal patients with luminal A or B breast cancer tumor subtypes.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1310-1317. doi:10.1001/jamaoncol.2019.1022

This cohort study evaluates the feasibility, risks, and advantages of resuming immune checkpoint inhibitor therapy in patients with cancer who experienced severe immune-related adverse events.

Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers

Abstract Full Text
has audio
JAMA Oncol. 2019;5(9):1318-1324. doi:10.1001/jamaoncol.2019.1402

This cohort study uses data from the Southern Community Cohort Study to evaluate whether race-specific adjustment of pack-year criteria in the US Preventive Services Task Force (USPSTF) lung cancer screening guidelines is associated with more equitable screening for African American smokers at high risk for lung cancer.

Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers

Abstract Full Text
JAMA Oncol. 2019;5(9):1325-1331. doi:10.1001/jamaoncol.2019.1208

This review of data from 75 families with a CDH1 pathologic variant compares estimates of the lifetime risk of gastric cancer in the families found to have a CDH1 pathologic variant through clinical ascertainment with those ascertained through multigene panel testing.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

Abstract Full Text
has multimedia
JAMA Oncol. 2019;5(9):1332-1339. doi:10.1001/jamaoncol.2019.2244

This open-label, nonrandomized, phase 1 study assesses the safety of pembrolizumab in patients with HIV and advanced cancer.

National and State Estimates of Lost Earnings From Cancer Deaths in the United States

Abstract Full Text
online only
JAMA Oncol. 2019;5(9):e191460. doi:10.1001/jamaoncol.2019.1460

This population-based study estimates earnings lost owing to death from cancer in the United States nationally and by state.

HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States

Abstract Full Text
online only
JAMA Oncol. 2019;5(9):e191742. doi:10.1001/jamaoncol.2019.1742

This database study compared cancer-specific mortality in HIV-infected vs HIV-uninfected elderly patients after adjusting data for receipt of specific cancer treatments.

Research Letter

Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017

Abstract Full Text
JAMA Oncol. 2019;5(9):1358-1359. doi:10.1001/jamaoncol.2019.1760

This review of novel oncology drugs approved by the US Food and Drug Administration examines the use of surrogate end points for overall survival, evaluates the use of patient-reported outcomes in trials supporting approvals, and seeks to determine whether drugs initially approved without evidence of overall survival or patient-reported outcome benefits demonstrate improvements in either measure postapproval.

Variations in Surgical Safety According to Affiliation Status With a Top-Ranked Cancer Hospital

Abstract Full Text
JAMA Oncol. 2019;5(9):1359-1362. doi:10.1001/jamaoncol.2019.1808

This database study analyzes the association between hospital affiliation with top-ranked cancer hospitals and surgical safety at affiliate hospitals.

Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non–Hodgkin Lymphoma

Abstract Full Text
JAMA Oncol. 2019;5(9):1362-1364. doi:10.1001/jamaoncol.2019.2203

This study uses whole-genome sequencing to examine whether survivors of childhood lymphoma who are carriers of BRCA2 gene mutation have a greater likelihood of developing adult-onset cancers.

Review

Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(9):1347-1354. doi:10.1001/jamaoncol.2019.0034

This review examines the main toxic effects of phosphatidylinositol 3-kinase inhibitors and recommends approaches to identification and management of such toxic effects.

JAMA Oncology Clinical Challenge

Cutaneous Scapular Lesion in an Elderly Woman

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(9):1355-1356. doi:10.1001/jamaoncol.2019.1754

A woman in her 80s presented with weight loss and a violaceous, cutaneous lesion of the scapula that grew from 3 cm to 30 cm in 5 months. What is your diagnosis?

Viewpoint

The Role of Medicare Reimbursement in Determining Access to Palliative Radiotherapy During Hospice Care

Abstract Full Text
JAMA Oncol. 2019;5(9):1257-1258. doi:10.1001/jamaoncol.2019.2308

This Viewpoint describes the barriers to accessing beneficial palliative care under the current Medicare reimbursement structure for hospice.

Patient-Reported Outcomes in Routine Care—A True Innovation but Only If Used Correctly

Abstract Full Text
JAMA Oncol. 2019;5(9):1258-1260. doi:10.1001/jamaoncol.2019.2321

This Viewpoint explains the importance of patient-reported outcome measures and suggests questions that physicians should ask when determining which set of patient-reported outcome measures to use for an individual patient.

Beyond Parity and Toward Socially Owned Anticancer Drug Research

Abstract Full Text
JAMA Oncol. 2019;5(9):1260-1261. doi:10.1001/jamaoncol.2019.2291

This Viewpoint describes the current anticancer drug–pricing strategy and advocates for a change to a socially owned model.

Editorial

Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1262-1264. doi:10.1001/jamaoncol.2019.1447
Invited Commentary

Radiotherapy and Immunotherapy—Shining Further Together

Abstract Full Text
JAMA Oncol. 2019;5(9):1291-1292. doi:10.1001/jamaoncol.2019.1448

Monoclonal Gammopathy May Be of Unpredictable Significance

Abstract Full Text
JAMA Oncol. 2019;5(9):1302-1303. doi:10.1001/jamaoncol.2019.1580
JAMA Oncology Patient Page

Online Cancer Information and Patient Groups

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1376. doi:10.1001/jamaoncol.2019.1576

This JAMA Patient Page describes cancer-related information and groups available online and explains how to determine whether these sources of information are trustworthy.

Cancer Care Chronicles

The Sciency Stuff

Abstract Full Text
JAMA Oncol. 2019;5(9):1255-1256. doi:10.1001/jamaoncol.2019.1898

This essay describes a medical physicist’s interaction with a patient and the profound effect that even the smallest patient interactions can have on health care professionals.

Comment & Response

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin

Abstract Full Text
JAMA Oncol. 2019;5(9):1364. doi:10.1001/jamaoncol.2019.1879

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin

Abstract Full Text
JAMA Oncol. 2019;5(9):1365. doi:10.1001/jamaoncol.2019.1882

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin

Abstract Full Text
JAMA Oncol. 2019;5(9):1365-1366. doi:10.1001/jamaoncol.2019.1890

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin

Abstract Full Text
JAMA Oncol. 2019;5(9):1366-1367. doi:10.1001/jamaoncol.2019.1893

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(9):1367. doi:10.1001/jamaoncol.2019.1901

Germline Variants in Highly Selected Patients With Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1367-1368. doi:10.1001/jamaoncol.2019.2106

Germline Variants in Highly Selected Patients With Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1368-1369. doi:10.1001/jamaoncol.2019.2115

Germline Variants in Highly Selected Patients With Prostate Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(9):1369. doi:10.1001/jamaoncol.2019.2120

Quality Assessment of a Systematic Review for HIV Infection and Advanced-Stage Cancer

Abstract Full Text
JAMA Oncol. 2019;5(9):1369-1370. doi:10.1001/jamaoncol.2019.2200

Quality Assessment of a Systematic Review for HIV Infection and Advanced-Stage Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(9):1370-1371. doi:10.1001/jamaoncol.2019.2206

The Use of e-Cigarettes in Patients With Cancer—A Double Shipwreck

Abstract Full Text
JAMA Oncol. 2019;5(9):1371. doi:10.1001/jamaoncol.2019.2384

The Use of e-Cigarettes in Patients With Cancer—A Double Shipwreck—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(9):1372. doi:10.1001/jamaoncol.2019.2396
Correction

Error in Results

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1372. doi:10.1001/jamaoncol.2019.3296

Corrected Disclosures Statement

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1372. doi:10.1001/jamaoncol.2019.3356

Errors in the Results Section and Table

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1372. doi:10.1001/jamaoncol.2019.3803
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1249. doi:10.1001/jamaoncol.2018.4780
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(9):1247. doi:10.1001/jamaoncol.2018.4779
×